法国镰状细胞病患病率与成本真实世界分析数据表

数据集获取（Figshare）

• 源站标题：Table_1_Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.DOCX
• DOI：10.3389/fpubh.2023.1215605.s001
• 发布日期：2023-09-21
• 文件数：1 个
• 文件总体积：40.62 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_Prevalence_and_cost_of_sickle_cell_disease_in_France_real-world_analysis_using_data_from_the_Echantillon_G_n_raliste_des_B_n_ficiaires_DOCX/24172941

命令行下载

curl -L -o "Table_1_Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.DOCX" "https://ndownloader.figshare.com/files/42413325"

文件清单

• Table_1_Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.DOCX（40.62 KB）

文件总体积 40.62 KB（源站 API 实测）。

数据说明

Sickle cell disease (SCD) is a genetic disorder of the hemoglobin resulting in chronic anemia, hemolysis, and vaso-occlusions. Its treatment mostly relies on hydroxycarbamide, transfusions, and stem cell transplantation. This study aimed at describing the epidemiology and management of SCD in adolescent and adult patients in France. This was a retrospective study performed among SCD patients aged ≥12 years between 2016 and 2018 and controls. SCD patients were matched on a 1:3 ratio with a group of individuals with no diagnosis of SCD, referred as control group. The matching of SCD patients and controls was a direct matching based on age, sex, CMU-c status (which corresponds to free-of-charge complementary coverage for people with low resources) and geographical region of residence. SCD patients and their matched controls were followed-up for the same amount of time by adjusting controls’ follow-up period to that of the associated patients. This study used claims data from the French representative 1/97th sample of health data system. The main outcomes were the patients’ characteristics and treatments received, healthcare consumptions and related costs among SCD cases and controls. Between 2016 and 2018, 151 patients with ≥6 months of follow-up were identified out of the total population of 732,164 individuals. SCD prevalence extrapolated to the entire population [95% CI] was 19,502 [19,230, 19,778] in 2018. The median (Q1–Q3) age at inclusion date was 37.0 (25.0–48.0) years, with 69.5% of patients being female. The mean (SD) reimbursed cost over follow-up was €24,310 (89,167), mostly represented by hospitalization costs accounting for €21,156 (86,402). A switch in SCD management was observed with age, as younger patients presented more frequent hospitalizations and acute procedures, while older ones had more frequent medical visits and paramedical care. Mean (SD) annual costs were €25,680 (91,843) and vs. €3,227 (23,372) for patients and controls, respectively (p < 0.001), representing an extra cost of almost €150 million over the entire SCD population. This study highlighted the important costs related to SCD and the related medical need with treatment alternat

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fpubh.2023.1215605.s001（source: https://frontiersin.figshare.com/articles/dataset/Table_1_Prevalence_and_cost_of_sickle_cell_disease_in_France_real-world_analysis_using_data_from_the_Echantillon_G_n_raliste_des_B_n_ficiaires_DOCX/24172941）。